Short Report of a Phase II Trial of Nintedanib in Recurrent Malignant Pleural Mesothelioma (MPM).

•Novel therapies are needed for the treatment of malignant pleural mesothelioma (MPM).•Agents targeting angiogenesis such as bevacizumab have a role in the treatment of MPM.•Nintedanib had modest activity involving prolonged stable disease in a small group of patients.•Immunotherapy is now important in the treatment of MPM but angiogenesis inhibitors in combination with immunotherapy and/or chemotherapy may still have a role.•It is very important to discover biomarkers that can help with patient selection to individualize treatment.•Participation in clinical trials evaluating novel agents remains very important in advancing treatment strategies.